Company Overview of Eurofarma Laboratórios S.A.
Eurofarma Laboratórios S.A. produces and markets medical prescription, veterinary, and over-the-counter drugs. It also offers medicines for hospital use, which include antibiotics, anesthetics, antifungals, antivirals, uterine stimulants, exchange resins, anti-ulcer, anti-inflammatory, and anticoagulant drugs; and serums in bags and jars. In addition, the company provides antiparasitic, vitamins, and tonics for the prevention and treatment of diseases primarily in cattle; and oncology drugs. Further, it manufactures medicines of various therapeutic classes and in various dosage forms, including cosmetics and hygiene products to other laboratories. Further, the company offers ampoules and via...
Av. Vereador José Diniz, nº 3465
São Paulo, SP 04603-003
Founded in 1972
Key Executives for Eurofarma Laboratórios S.A.
Eurofarma Laboratórios S.A. does not have any Key Executives recorded.
Eurofarma Laboratórios S.A. Key Developments
Eurofarma Laboratórios S.A. Presents at BIO-Europe 2015, Nov-02-2015
Oct 1 15
Eurofarma Laboratórios S.A. Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.
Ceyoka (Pvt) Ltd. Signs Distributor Pact with Eurofarma
Jul 10 15
Ceyoka (Pvt) Ltd. signed a milestone exclusive distributor agreement with Eurofarma. Under the terms of the exclusive agreement (oncological products), Ceyoka has received the sole legal rights from Eurofarma to import, stock, promote, market and distribute its range of pharmaceuticals in Sri Lanka. The landmark agreement with Ceyoka, signals the first foray by a Brazil based multinational pharmaceutical company in to the country. Ceyoka retains the exclusive right in Sri Lank to promote and distribute products under the Eurofarma trade mark.
Melinta Therapeutics, Inc. Partners with Eurofarma Laboratorios S.A
Jan 12 15
Melinta Therapeutics, Inc. and Eurofarma Laboratorios S.A. have entered into commercialization and distribution agreements for delafloxacin, an investigational fluoroquinolone. Under the terms of the agreements, Eurofarma will be responsible for obtaining regulatory approval in Brazil and will then have the right to market, sell and distribute delafloxacin in that country for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta will receive a combined upfront cash and equity payment of $15 million, as well as milestones and royalties on future sales of delafloxacin.
Similar Private Companies By Industry
Recent Private Companies Transactions